Expansion Opportunities GSK is accelerating investment in the UK with a £400 million Cambridge research campus and broader UK facilities expansion. This presents sales opportunities for research infrastructure, data analytics, lab services, and collaborative innovation platforms aligned with life sciences clusters.

R&D Acceleration Strategic emphasis on speeding pipeline and competitive medicines suggests demand for advanced analytics, data management, and collaboration tools to streamline clinical trials, biomarker discovery, and drug development workflows.

Vaccine and Therapeutics Focus With a portfolio spanning vaccines and medicines and a WHO priority-disease research stance, there is potential for partnerships in vaccine manufacturing support, supply chain optimization, and targeted R&D platforms that enable rapid response capabilities.

Digital & Analytics GSK’s tech stack includes analytics platforms and data tooling (Teradata, Weaviate, Visier, etc.), indicating openness to expand data lake, analytics, AI, and cloud modernization initiatives to improve insights across commercial and scientific operations.

Commercial Leadership Leadership changes and a focus on building a competitive drug pipeline suggest opportunities in CRM, digital marketing solutions, omnichannel engagement, and sales enablement tools to support global go-to-market activities.